Principle Wealth Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Principle Wealth Partners’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,000	Closed	-$357K	–	341
2024 Q1	$357K	Hold	15,000	–	–	0.03%	260
2023 Q4	$324K	Hold	15,000	–	–	0.03%	259
2023 Q3	$218K	Hold	15,000	–	–	0.02%	300
2023 Q2	$314K	Hold	15,000	–	–	0.03%	258
2023 Q1	$317K	Hold	15,000	–	–	0.03%	250
2022 Q4	$382K	Buy	+15,000	New	+$350K	0.04%	221
2022 Q3	–	Sell	-14,000	Closed	-$269K	–	304
2022 Q2	$269K	Sell	14,000 -6,500	-32%	-$108K	0.03%	261
2022 Q1	$356K	Hold	20,500	–	–	0.04%	239
2021 Q4	$449K	Hold	20,500	–	–	0.05%	215
2021 Q3	$392K	Hold	20,500	–	–	0.05%	224
2021 Q2	$352K	Hold	20,500	–	–	0.04%	231
2021 Q1	$458K	Hold	20,500	–	–	0.05%	199
2020 Q4	$456K	Buy	+20,500	New	+$425K	0.06%	188

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Principle Wealth Partners's SNDX Position: Q2 2024 in Review

Principle Wealth Partners sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 15,000 shares — an estimated $357K sold.

Principle Wealth Partners first reported a position in SNDX in Q4 2020 and held it in 13 quarters. The position peaked at $458K in Q1 2021. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

Principle Wealth Partners reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Principle Wealth Partners sold 15,000 Syndax Pharmaceuticals shares in Q2 2024, an estimated $357K.
Principle Wealth Partners first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 13 quarters.
Principle Wealth Partners's Syndax Pharmaceuticals position peaked at $458K in Q1 2021.
196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on Principle Wealth Partners's 13F filing for Q2 2024, filed 13 Aug 2024.